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Abstract
Current treatment decisions for osteoporosis depend on the fracture risk calculated based on the results of comprehensive diagnostic
procedures [clinical risk factors (CRF), densitometry (BMD), morphometry, and bone turnover markers (BTM)]. Recently developed frac-
ture risk assessment tool (FRAXTM) represents an important new achievement as a 10-year fracture risk calculation based on femoral neck
densitometry and age combined with independent clinical fracture risk factors. FRAXTM presents several options: FRAXTM BMI (body mass
index) is advocated as a helpful screening tool to identify the group of patients with high fracture risk, independently of access to densito-
metry and FRAXTM, utilizing hip densitometry. In both cases, the probability of major fractures or hip fractures are calculated during
performed diagnostic evaluations. Operating FRAXTM algorithm does not include spinal bone mineral density, which is its main limitation.
With the aim of improvement of anti-fracture efficacy of therapeutic management of osteoporosis, we have extended our discussion to
three integral elements of existent strategy: 1) screening outlines, 2) principles of drug selection, and 3) treatment benefit evaluation.
Since osteoporosis is a chronic disease, long-term adherence to the treatment is important. The suitability of the drug, the patient’s prefe-
rence, tolerability, and convenience should all be considered. Anti-catabolic drugs are most appropriate in patients with high bone turno-
ver, while anabolic drugs demonstrate efficacy irrespective of bone turnover. BMD measurement is most widely used for long-term asses-
sment of the efficacy of osteoporosis treatment. The measurements of bone turnover markers (BTMs) can be considered a useful short-
term (at 3 months) monitoring tool in selected patients. In both BTM and BMD, the least significant change (LSC) method should be used
for interpretation of the results. Fractures are not a reliable clinical endpoint for evaluating the effectiveness of therapy in individual
patients because of their stochastic nature. If fractures occur, however, the need for drug change and additional non-pharmacological
treatment (fall prevention, balance training, muscle strengthening) should always be considered.
(Pol J Endocrinol 2009; 60 (2): 124–133)
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Streszczenie
Kryterium interwencji farmakoterapeutycznej w osteoporozie bez złamań stanowi ocena indywidualnego bezwzględnego 10-letniego
ryzyka złamań, określonego na podstawie kompleksowej analizy czynników ryzyka złamań. Kompleksowa ocena ryzyka złamań w per-
spektywie 10-letniej integruje wyniki badań diagnostycznych (densytometria, ocena bezobjawowych złamań kręgów, ocena metabolizmu
kostnego) oraz wybranych klinicznych czynników ryzyka złamań. Wprowadzony w 2008 roku kalkulator FRAXTM (WHO Fracture Risk
Assessment Tool) pozwala na szybkie i proste obliczanie 10-letniego ryzyka złamań, które u indywidualnego pacjenta powinno być pod-
stawą do podejmowania dalszych decyzji diagnostycznych i terapeutycznych. FRAXTM opracowany jako kalkulator obliczający 10-letnie
ryzyko złamań może być stosowany z uwzględnieniem densytometrii bliższej nasady kości udowej wraz z innymi niezależnymi czynni-
kami ryzyka złamań. FRAXTM oparty na wskaźniku masy ciała (BMI, body mass index), gęstości mineralnej kości (BMI, bez uwzględnienia
pomiaru BMD [bone mineral density]) może być przydatnym narzędziem przesiewowym dla lekarzy pierwszego kontaktu oceniających
ryzyko złamań (case finding strategy), zwłaszcza w przypadku ograniczonego dostępu do densytometrii. W obu przypadkach FRAXTM
może oceniać 10-letnie ryzyko złamania bliższej nasady kości udowej oraz wszystkich złamań osteoporotycznych. Głównym ogranicze-
niem algorytmu FRAXTM jest brak możliwości wykorzystania wyników badań densytometrycznych w lokalizacji kręgosłupa lędźwiowe-
go. O ile decyzja, co do potrzeby leczenia farmakologicznego osteoporozy opiera się głównie na wielkości przewidywanego 10-letniego
ryzyka złamania, to zasadniczymi kryteriami wyboru leku u indywidualnego pacjenta powinny być skuteczność przeciwzłamaniowa
leku, oceniana w randomizowanych, kontrolowanych badaniach klinicznych, oraz potencjalne działania niepożądane, dostępność i łatwość
stosowania. Na wybór leku wpływa także mechanizm jego działania: leki przeciwresorpcyjne są najbardziej skuteczne u chorych z za-
awansowanym zanikiem kostnym i szybkim obrotem metabolicznym kości, podczas gdy leki anaboliczne lub podwójnym punkcie uchwytu
(ranelinian strontu) działają niezależnie od wyjściowych wartości BMD czy aktywności obrotu kostnego. „Złotym standardem” leczenia
osteoporozy pozostają bisfosfoniany. Ocena efektywności prowadzonej farmakoterapii jest jednym z ważniejszych elementów strategii
w postępowaniu przeciwzłamaniowym. Pomiar BMD jest uznanym długoterminowym wskaźnikiem zastępczym oceny wytrzymałości
mechanicznej kości. Wskaźnikiem krótkoterminowym oceny efektywności terapii (3 miesiące) jest pomiar poziomu markerów obrotu
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kostnego w surowicy. W obu przypadkach podstawowym kryterium interpretacyjnym powinna być najmniejsza znacząca zmiana (LSC,
least significant change). Interpretacja znaczenia złamania kości w trakcie terapii antyzłamaniowej jest niejednoznaczna. Złamań nie należy
interpretować jako bezwzględnego wskaźnika braku efektywności stosowanej farmakoterapii, należy jednak ponownie zanalizować dane
pacjenta, wprowadzając zwłaszcza modyfikację postępowania niefarmakologicznego. (Endokrynol Pol 2009; 60 (2): 124–133)
Słowa kluczowe: złamania, BMD, markery obrotu kostnego, osteoporoza, FRAXTM, bisfosforany, PTH
Introduction
To improve the antifracture efficacy of therapeutic mana-
gement of osteoporosis, three key issues are overviewed.
1. Selection of the most effective screening strategy to
identify patients at high risk of osteoporotic fractu-
res with the aim of achieving the best sensitivity,
with use of clinical risk factors (CRF), bone mineral
density (BMD) or bone turnover markers (BTM)
compromised in the form of a semi quantitative or
quantitative model of FRAXTM, in both cases direc-
ted to hip or to all osteoporotic fractures.
2. Improvement and evaluation of pharmacological
management with a focus on the mechanisms of the
action of drugs used in osteoporosis, such as anti-
catabolic treatments (bisphosphonates, hormonal
therapy, SERMs, calcitonin), proanabolic treatments
(teriparatide), or dual-action treatments (strontium
ranelate).
3. To overcome problems of low compliance and per-
sistence in osteoporosis therapy, the development
of short and long-term monitoring strategies for the
evaluation of proper use of drugs utilized in therapy,
and evaluation of their effectiveness.
Limitations of definition of osteoporosis
and its consequences
Osteoporosis is defined as a systemic skeletal disease
characterised by low bone mass and microarchitectural
deterioration of bone tissue, with a consequent incre-
ase in bone fragility and susceptibility to fractures [1].
The definition of osteoporosis based on low bone mass
is invalidated by several problems, principally because
of the lack of a clear-cut discrimination point. It does
not provide explicit diagnostic criteria that allow one to
decide whether an individual is osteoporotic, nor does
it specify the cause or the pathogenesis mechanisms of
low bone mass or poor microarchitectural state. It also
does not refer to the underlying mechanisms concer-
ning relation to inactivity, aging, or developed material
properties [1–6].
Osteoporosis is a common and debilitating disease.
Worldwide, the lifetime risk for women having an oste-
oporotic fracture is estimated at 30–40%. Furthermore,
new studies have shown the prevalence of osteoporo-
sis in men as higher than previously thought — with
approximately one in five men affected. Generally,
osteoporosis can be diagnosed in one of two ways — cli-
nically, especially in the presence of fragility fractures, and
in more difficult situations when related to the prefractu-
re stage. In the latter, with use of clinical risk factors densi-
tometry when necessary extended with morphometry and
bone metabolism estimations for establishing the poten-
tial fragility and fracture risk of analyzed subjects.
Osteoporotic fracture
The definition of an osteoporotic fracture is not stra-
ightforward [1–3]. A widely adopted approach is to con-
sider fractures from low energy trauma as being oste-
oporotic. Low energy may variously be defined as a fall
from a standing height, or trauma that in a healthy in-
dividual would not give rise to fracture. This characte-
rization of low trauma indicates that the vast majority
of hip and forearm fractures are low energy injuries. At
the age of 50 years, approximately 75% of people ho-
spitalized for vertebral fractures have fractures that are
attributable to low energy injuries, increasing to 100%
by the age of 90 years.
The rising incidence of fractures with age does not
provide direct evidence for osteoporosis, since a rising
incidence of falls could also be a cause. By contrast,
a lack of increasing incidence of fractures with age is
reasonable presumptive evidence that a fracture is unli-
kely to be osteoporosis related.
In women, fracture incidence begins to increase aro-
und the age of fifty (time of menopause), and in men
the increase begins later, in about the mid sixties. These
fractures in the older age groups are typically the result
of minimal trauma and occur at the hip, spine, and wrist
(the most common sites of osteoporotic fractures) with
incidence of them higher in women than in men.
Despite a large number of studies that have exami-
ned the incidence of fractures by age and sex, our know-
ledge of the incidence and the pattern of fractures worl-
dwide is incomplete.
Hip fractures, the second most common osteoporo-
tic fracture, are usually caused by a fall from standing
height usually with a subsequent requirement of hospi-
talization and surgery. Nevertheless, it should be poin-
ted out that most falls do not result in fracture, with only
about 1–2% of falls in the elderly causing a hip fracture.
Vertebral fracture prevalence is very difficult to
ascertain, as it is estimated that only about 30% of “mor-
phometric” fractures are clinically apparent. The third
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most common osteoporotic fractures are distal forearm
fractures, caused mostly by a fall on an outstretched
hand. These fractures tend to occur at younger ages,
and about 20% result in hospitalization.
Osteoporosis, even with fractures, frequently goes
unrecognized in the clinical setting, with many studies
showing that fewer than 20% of patients with osteopo-
rotic fractures receive a diagnosis of osteoporosis. An
even smaller percentage of those diagnosed are treated
for osteoporosis.
Diagnosis of non-fracture patients and
limitations of traditional WHO definitions
Diagnosis of non-fractures patients, until recent
years, was based on densitometry, the most widely va-
lidated technology for the assessment of skeletal health,
and used the T-score expressed as standard deviation
(SD) difference between the BMD of a patient and that
of a young adult female reference population [4, 5].
The widespread clinical use of DXA, particularly at
the proximal femur and lumbar spine (central DXA),
arises from many prospective studies that have docu-
mented a strong gradient of risk for fracture prediction.
The following four general descriptive categories are
given for adult men and women using measurements
of DXA at the femoral neck, spine, and forearm, sum-
med up in the so-called WHO criteria (Table I).
From one side, operationally, BMD when assessed
by dual-energy X-ray absorptiometry (DXA). DXA of
central skeletal sites (spine and hip) is considered the
“gold-standard” method for the diagnosis of osteopo-
rosis and monitoring changes in BMD because:
— biomechanical studies have shown a strong correla-
tion between mechanical strength and BMD measu-
red by DXA;
— large epidemiological studies have established
a strong relationship between fracture risk and BMD
measured by DXA;
— the World Health Organization (WHO) classifica-
tion of BMD for the diagnosis of osteoporosis and
osteopaenia is largely based on reference data obtai-
ned by DXA;
— most randomized clinical trials showing a benefit
with pharmacological intervention have selected
subjects based on low BMD measured by DXA;
— there is a relationship between reduction in fractu-
re risk with pharmacological therapy and BMD in-
crease measured by DXA;
— DXA accuracy and presentation are excellent. A T-score
of –2.5 or less at the femoral neck, total hip, lumbar
spine, or one-third (33%) radius is considered a dia-
gnosis of osteoporosis [4].
On the other, it appeared that although bone mass
is an important component of the risk of facture, other
abnormalities occur in the skeleton that contribute to
fragility. It has become apparent that the presence of
several risk factors used to trigger a BMD test are asso-
ciated with a fracture risk much greater than can be ac-
counted for by BMD alone. In addition, the vast majo-
rity of fractures appeared in the range of T-score lower
than –2.5.
Since BMD forms just one component of fracture
risk, accurate assessment of fracture risk should ideally
take into account other readily measured indices of frac-
ture risk that add information to that provided by BMD.
Many cross-sectional prospective population studies
indicate that the risk of fracture increases by a factor of
1.5 to 3.0 for each standard deviation decrease in BMD.
Low sensitivity is one of the reasons why widespread
population-based screening with BMD is not widely
recommended in women at the time of menopause.
There are also a number of limitations in the general
application of DXA for diagnosis that should be reco-
gnised. The presence of osteomalacia, a complication
of poor nutrition in the elderly, will underestimate total
bone mass because of decreased mineralisation of bone.
Osteoarthritis and osteoarthrosis of the spine and/or hip
are common in the elderly, and contribute to the densi-
ty measurement, but not necessarily to skeletal strength.
Heterogeneity of density also appears due to osteoar-
throsis. Presently there are no satisfactory clinical tools
available to assess bone quality independently of bone
density, so for practical purposes the assessment of oste-
oporosis depends upon the measurement of skeletal
mass, as assessed by measurements.
Lately a large number of additional risk factors for
fracture have been identified. For the purposes of risk
assessment, interest is centred around factors that con-
tribute significantly to fracture risk over and above that
provided by BMD measurements or age.
Moreover, BMD measurements lack sensitivity over
clinical assessment of fracture risk, i.e., the detection rate
is low. For example, at the age of 50 years the propor-
tion of women with osteoporosis is approximately 5%;
however, the proportion of these who will fracture in
the next 10 years is about 20%. The detection rate for
Table I. WHO/NOF diagnostic criteria (DXA)
Tabela I. Kryteria diagnostyczne WHO/NOF (DXA)
T-score
Normal > –1.0
Osteopenia (low bone mass) –1.0 to –2.5
Osteoporosis < –2.5
Established osteoporosis < –2.5 + fracture
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these fractures (sensitivity) is low, and in fact, up to 96%
of fragility fractures would arise in women without oste-
oporosis diagnosed, according to WHO BMD diagno-
stic criteria. Low sensitivity is one of the reasons why
widespread population screening is not widely recom-
mended in women during menopause [7].
The development of FRAX TM
Over the past few years a series of meta-analyses has
been undertaken to identify clinical risk factors that
could be used in case finding strategies, with or witho-
ut the use of BMD (Table II).
The WHO Collaborating Centre for Metabolic Bone
Diseases at Sheffield has developed algorithms to com-
pute age-specific fracture probabilities in men and wo-
men, from CRFs and BMD measurement at the femo-
ral neck. The algorithms (FRAXTM) are based on a series
of meta-analyses using several identified CRFs for frac-
ture. The performance characteristics of these CRFs have
been validated in independent, population-based, pro-
spectively studied cohorts with over a million per-
son-years of observation. The FRAXTM tools calculate the
10-year probability of a major osteoporotic fracture (clini-
cal spine, hip, forearm, or proximal humerus) or hip frac-
ture calibrated to the fracture and death hazards [7–10].
A fracture risk assessment tool (FRAXTM trademark)
was developed based on the use of clinical risk factors
with or without bone mineral density tests applied. The
aim of this was to apply an assessment tool for the pre-
diction of fractures in men and women with the use of
clinical risk factors (CRFs) for fractures with and witho-
ut the use of femoral neck bone mineral density (BMD).
The clinical risk factors, identified from previous meta-
analyses, comprised body mass index (BMI, as a conti-
nuous variable), a prior history of fracture, a parental
history of hip fracture, use of oral glucocorticoids, rheu-
matoid arthritis and other secondary causes of osteopo-
rosis, current smoking, and alcohol intake of 3 or more
units daily.
BMD and skeletal risk factors
— semi quantitative model
In circumstances of limited adaptation of FRAXTM to
routine clinical practice, patients in the presence of risk
factors and low bone mass at the spine can alternative-
ly use an algorithm based on that developed by the
Osteoporosis Society of Canada’s “Recommendations
for Bone Mineral Density Reporting”, which estimates
the 10-year probability of fracture using the lowest BMD
measured in alternative central sites (lumbar spine [LS],
femoral neck [FN], total hip, and distal 1/3 radius, if in-
dicated). Demonstration of an established high 10-year
probability of major osteoporotic fracture is an indica-
tion to initiate drug treatment [11]. In patients with
moderate risk, the presence of any of the following risk
factors [family history of fractures, demonstration of
vertebral fractures on X-ray or VFA, long-term gluco-
corticosteroid treatment: (prednisone at more than
5 mg/day for more than 3 months), increased bone me-
tabolism in postmenopausal women measured by bone
turnover markers], which undoubtedly doubles the es-
timated fracture risk, shifts the fracture probability from
the moderate level to the high level, and suggests that
initiation of pharmacological treatment should be con-
sidered. According to the estimated prevalence of frac-
tures in Poland, demonstration of a 10-year probability
of more than 20% should be considered as high, and
between 10% and 20% as moderate (Table III). Ten-year
fracture risk values of more than 20% are recognized in
this case as an indication for treatment.
Bone turnover markers
One important determinant of bone strength that is not
assessed by either BMD or clinical factors is the rate of
bone remodelling measured by BTMs [12].
BTMs help to detect postmenopausal women who
are at high risk of all osteoporotic fractures indepen-
dently of age, BMD, and prior fracture [12–15]. This as-
sociation has been assessed prospectively in longitudi-
nal cohort studies and case-control studies. Osteopenic
women with high BTM levels have a risk of fracture
similar to that of osteoporotic women based on BMD,
whereas osteopenic women with normal BTM levels
have a fracture risk that is comparable to that of post-
menopausal women with normal BMD [15].
Whether the pre-treatment (baseline level) BTM con-
centrations are predictive of a greater response to any
of the anti-osteoporotic drugs remains controversial [12].
Table II. Most frequently analyzed risk factors
Tabela II. Najczęstsze czynniki uwzględniane w ocenie ryzyka
Low body mass index (BMI)
A history of fragility fracture is an important risk factor
for further fracture
A family history of fragility fractures is a significant risk
factor that is largely independent of BMD
Cigarette smoking
Glucocorticoids
Alcohol
Rheumatoid arthritis
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In post-hoc analysis of the Fracture Intervention Trial
(FIT) alendronate non-spine fracture efficacy was gre-
ater among women with high pre-treatment N-termi-
nal propeptide of type I collagen (P1NP) [16]. For oste-
oporotic woman in the lowest tertile of pre-treatment
P1NP, the alendronate versus placebo, the relative ha-
zard for non-spine fracture, was 0.88 compared to the
relative hazard of 0.54 among those in the highest terti-
le of P1NP. Similar results were observed among wo-
men without osteoporosis at baseline. A pharmacoeco-
nomic study (Markov model) [14] concluded that me-
asurement of BTMs has the potential to identify a sub-
set of postmenopausal women (top BTM quartile),
without osteoporosis by BMD criteria, for whom alen-
dronate therapy to prevent fracture is cost-effective.
Additional information provided by BTMs can af-
fect clinical decisions, increasing identification, sensiti-
vity, and specifity of subjects at risk of fractures.
The large biological variability of BTM determinations
by different methods was previously a significant obstac-
le to its broader use in clinical settings. However, automa-
ted immunoassays with ECLIA devices for serum deter-
mination of OC, P1NP, and CTX and diagnostic standards
of GLP in pre-laboratory steps introduced in the last
2 years have made bone turnover marker determination
a routine endocrinological diagnostic procedure [17,18].
In order to make use of the clinical potential of BTM,
appropriate reference ranges are crucially important.
Recommended normal reference ranges for premeno-
pausal women were recently published for OC, CTX,
and P1NP determined with ECLIA automated immu-
noassay as standard procedure [19–21] as well as a scat-
ter plot identifying postmenopausal woman belonging
to an elevated bone turnover marker subgroup using
two markers in the Polish population [22]. With these
tools, the appropriate identification of postmenopausal
women with high and low bone turnover is possible.
Therapeutic threshold
Diagnostic thresholds differ from intervention thre-
sholds in several ways. When diagnostic values combi-
Table III. Ten-year fracture risk (FR) depending on sex, age, and BMD T-score (according to 2005 OSC Recommendations for
Bone Mineral Density Reporting)
Tabela III. Dziesięcioletnie ryzyko złamania w zależności od płci, wieku i T-score dla BMD
Women
Age (years) T-score
> –2.0 –2.0 to –2.5 –2.5 to –3.0 –3.0 to –3.5 –3.5 to –4.0 < –4.0
50 Low Moderate Moderate Moderate Moderate High
55 Low Moderate Moderate Moderate High High
60 Low Moderate Moderate High High High
65 Moderate Moderate High High High High
70 Moderate Moderate High High High High
75 Moderate High High High High High
80 Moderate High High High High High
85 Moderate High High High High High
Men
Age (years) T-score
> –2.0 –2.0 to –2.5 –2.5 to –3.0 –3.0 to –3.5 –3.5 to –4.0 < –4.0
50 Low Low Low Low Moderate Moderate
55 Low Low Low Moderate Moderate Moderate
60 Low Low Low Moderate Moderate Moderate
65 Low Low Moderate Moderate Moderate Moderate
70 Low Moderate Moderate Moderate Moderate High
75 Moderate Moderate Moderate High High High
80 Moderate Moderate Moderate High High High
85 Moderate Moderate Moderate High High High
FR <10% FR 10–20% FR >20%
FR — fracture risk;        Low risk of fracture (<10%);         Moderate risk of fracture (10–20%);        High risk of fracture (>20%)
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ne estimated fracture probabilities and are based on the
presence of clinical risk factors: densitometry, morpho-
metry, and high bone turnover data, intervention thre-
sholds will also be focused on the determination of the
cost and benefits of treatment. The fact that fracture risk
varies markedly in different populations and different
nations is important for establishing therapy. For exam-
ple, in women with a T-score of –2.5 SD, the probability
of hip fracture is 5 times greater at the age of 80 years
than at the age of 50 years. Moreover, it seems that
multiplicative relation of fracture risk to BMD is accep-
table for low risk, but not for moderate/high risk. This
observation is inline with the estimation of Kanis et al. [7],
showing that absolute risk increases linearly with RR in
young women (i.e. multiplicatively), but slower than
RR in older women. There also significant differences
in absolute fracture risk in different countries. Since the
present approaches to the identification of patients at
risk for fracture focus selection on a few clinical factors
and estimation of femoral neck BMD, more informa-
tion is required.
A potential list of other significant risk factors, the
validity of which would permit further refinements to
the models available, would include clinical risk factors
for falls, the use of DXA at other skeletal sites such as
the total hip and lumbar spine, indices of bone turno-
ver and the use of other technologies such as quantita-
tive ultrasound, and secondary causes of osteoporosis
other than rheumatoid arthritis. Assessment algorithms
should also be further validated in male and non-Cau-
casian populations.
Case-finding strategies also require broader valida-
tion in clinical trials, to test whether pharmacological
agents reduce fracture risk in individuals identified by
the use of clinical risk factors, with and without the se-
lective use of BMD.
Principles for drug selection in osteoporosis
Treatment decisions in osteoporosis should be based on
the absolute risk of fracture (FRAXTM) calculated by
means of a patient’s clinical risk factors and BMD, and
in selected cases on the assessment of bone metabolic
rate using biochemical markers of bone turnover. In all
cases of low bone mass or low-trauma fractures, diffe-
rential diagnosis should be performed to rule out se-
condary causes; however, causative management of
secondary osteoporosis does not exclude the need for
symptomatic anti-fracture pharmacotherapy [11].
The successful fracture prevention trial of alendro-
nate, a little over ten years ago, documented the drug’s
efficacy in fracture prevention [23]. This was a landmark
event in bone research, and was followed by successful
trials of other bisphosphonates, selective oestrogen re-
ceptor modulators (SERMs), calcitonin, strontium rane-
late, and parathormone analogues [24–35]. Consequen-
tly, drug selection in osteoporosis treatment started to
be based on the results of randomized, placebo-control-
led clinical trials demonstrating the effects of a given
intervention on fracture risk (Table IV). However, it is
worth remembering that no studies have directly com-
pared these therapies head-to-head for anti-fracture
efficacy [36–38].
The mechanism of action of the drug is the subject
of critical evaluation. Anti-catabolic drugs seem to be
the most appropriate in patients with high bone turno-
ver, while anabolic drugs demonstrate efficacy irrespec-
tive of bone turnover. Anabolic treatment should be
Table IV. Effect of various factors on anti-fracture efficacy of registered antiosteoporotic drugs in pivotal RCT’s
Tabela IV. Wpływ różnych czynników na skuteczność w zapobieganiu złamaniom zarejestrowanych leków przeciwosteoporotycznych
w najważniejszych badaniach z randomizacją i grupą kontrolną
BMD osteopenia BMD osteoporosis Previous fracture Bone tumover
VFx risk HipFx risk VFx risk HipFx risk Previous Previous Previous High Normal
 VFx (–) VFx (+) HipFx (+) (premenopausal)
ALN + ø + + + + ND + ø
RIS ND ND + +1 ND + ND
IBN ND ND + +2 ND + ND
ZOL ND ND + + + + +
CT ND ND + ø ND + ND
RAL + ø + ø + + ND
PTH ND ND + + ND + ND
RS + ND + + + + ND + +
ND — no data; 1in high-risk population (age > 70, FN T-score < –4.0 or –3.5 and clinical risk factors); 2FN T-score < –3.0; VFx (+) — vertebral
fracture; HipFx (+) — hip fracture
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particularly indicated in patients with low bone forma-
tion in the elderly, in patients with glucocorticoid-in-
duced osteoporosis, and in patients with extremely low
bone mass, or after multiple fractures, where preserva-
tion of bone mass and bone architecture by anti-cata-
bolic drugs is not sufficient to reduce efficiently high
absolute risk of fracture [11].
Co-morbidities and safety for bone and other tissu-
es (non-skeletal risks and benefits) of the drug were
considered when registered, and utilized.
Calcium and vitamin D supplements are the main-
stay of prevention and are the necessary complement
of osteoporosis treatment. The recommended daily
doses of vitamin D3 and calcium are 800–2000 IU and
500–1500 mg, respectively [39–40].
Treatment of choice
All oral N-containing bisphosphonates showed a simi-
lar relative rate of vertebral fracture reduction in the
placebo-controlled, randomized clinical trials [36–38].
Modest differences in hip or nonvertebral fracture risk
reduction are difficult to compare due to differences in
the baseline patient characteristics and marked diffe-
rences in the dropout rate in those studies, and seem to
be of small clinical importance (Table IV) [41]. More-
over, recent observational studies including the evalu-
ation of a large number of community-based persons
initiating oral bisphosphonates therapy, based on ad-
ministrative claims databases of large commercial he-
alth care systems, showed similar absolute rates of both
vertebral and nonvertebral fractures between new users
of weekly alendronate vs. weekly risedronate [42, 43],
and weekly alendronate and risedronate vs. monthly
ibandronate [44]. Bisphosphonates are the most effecti-
ve in postmenopausal women and aging males with
established osteoporosis, especially with high bone tur-
nover. Present evidence does not prove the efficacy of
bisphosphonates in osteopenia (Table IV).
In fact, the main difference among various oral bi-
sphosphonates relates mostly to compliance and persi-
stence (adherence-to therapy). A once-a-month sche-
dule is better accepted by patients than a once-a-week
scedule [45, 46], which in turn seems to be better than
a daily schedule [47].
Intravenous bisphosphonates (ibandronate 3 mg
every 3 months, zoledronic acid 5 mg once a year) may
be particularly useful in the treatment of patients with
gastrointestinal pathologies and patients intolerant of
oral bisphosphonates, as well as patients chronically
immobilised (as a result of vertebral or hip fractures or
stroke), or those with dementia [30, 48, 49]. Once-year-
ly zoledronic acid therapy not only maintains bone mi-
croarchitecture, but also enables sufficient bone rene-
wal. Moreover, apart from the bone preserving effect,
zoledronic acid administered once a year guarantees
100% adherence to therapy.
Bisphosphonates are considered the treatment of
choice for the prevention of osteoporotic fractures in
postmenopausal women and men with prevalent low-
trauma vertebral or hip fractures, and in patients with
high 10-year fracture probability, particularly those with
advanced bone loss and/or high activity of bone turno-
ver markers [11].
Strontium ranelate, with its synchronous antiresorp-
tive and pro-anabolic effects, shows anti-fracture effi-
cacy in all types of osteoporotic fractures, both verte-
bral and nonvertebral, regardless of the initial BMD or
bone turnover (Table IV) [50]. It significantly reduces
the incidence of vertebral fractures in women with oste-
opaenia, and the probability of hip fractures in women
older than 80 years with low bone mineral density [51,
52]. Strontium ranelate is an alternative recommended
therapeutic option in postmenopausal women. It sho-
uld be considered as the treatment of choice in postme-
nopausal women with BMD values consistent with oste-
opaenia, independently of the bone turnover and in
women over the age of 80 [11].
Second-line treatment options
Raloxifene (SERM) may be considered in postmenopau-
sal women with low bone mass or younger postmeno-
pausal women with osteoporosis, who are at greater
risk of vertebral fracture than hip fracture. It prevents
bone loss and reduces the risk of vertebral fractures,
but its effectiveness in reducing other fractures is un-
certain (Table IV). Extraskeletal risk and benefits are im-
portant when considering raloxifene therapy [53–55].
Calcitonin is definitely not a first-line drug for oste-
oporosis treatment, as its fracture efficacy is not strong
and its BMD effects are less than those of other agents.
It is, however, recommended for treating bone pain
from acute vertebral compression fracture.
Teriparatide is a highly effective bone anabolic agent,
which produces a highly significant reduction of osteopo-
rotic fractures of any type in patients with severe osteopo-
rosis (Table IV). Nowadays, this is the only medication to
restore bone structure independently of the degree of in-
itial disarrangement. However, the relative fracture reduc-
tion with anabolic treatment with PTH differs only a little
from that with adequately studied resorption inhibitors.
For safety reasons, the duration of treatment has been re-
stricted to 24 months. In order to maintain the achieved
therapeutic effects, continuation of treatment with bispho-
sphonates should be considered [56–59].
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Combining anti-catabolic drugs
The addition of bisphosphonates (alendronate, risedro-
nate) to long-term hormone therapy in postmenopau-
sal women results in a greater increase of bone mineral
density. Alendronate increases BMD by 3% at 2 years
in women receiving hormone therapy [60, 61]. Co-ad-
ministration of calcitonin and oestrogens, raloxifene,
and alendronate also increases BMD, although the ef-
fect of this treatment on the risk of fractures has not
been investigated. Due to the increased treatment co-
sts, multiplication of potential side effects, and the lack
of data on the potential superiority of the combined use
of antiresorptive drugs, this treatment is not recommen-
ded [11].
Treatment with teriparatide
and anti-catabolic drugs
Bisphosphonates used prior to, or in combination with,
PTH preparations reduce the anabolic effect of para-
thormone. However, the inclusion of bisphosphonates
after completion of treatment with a PTH preparation
maintains the previously achieved therapeutic effect
and promotes further increase of BMD. Conclusions
from the existing data should be drawn cautiously, due
to the lack of prospective studies, the small size of the
study population, and, especially, the lack of evaluation
of the effects of anti-catabolic treatment following com-
pletion of teriparatide treatment on the incidence of frac-
tures. It seems, however, that anti-catabolic treatment,
which prevents bone loss after discontinuation of teri-
paratide, should be recommended, and sequential tre-
atment with anabolic-followed by anti-catabolic drugs
offers the desirable benefits needed for long-term effi-
cacy [56–59].
Osteoporosis is a chronic disease; therefore, long-
term adherence (compliance and persistence) to the tre-
atment is most important. The suitability of the drug
for long-term administration, and factors such as pa-
tient preference, tolerability, and convenience are im-
portant factors influencing the final efficacy of the tre-
atment. Adherence to therapy in osteoporosis is poor.
In studies of 6 months to 1 year, adherence rates for
prescription drugs ranged from below 25% to 80%, de-
pending on the therapy [42, 62]. Ensuring adherence to
the treatment plan is perhaps the most important fol-
low-up measure for clinicians. It is important to identi-
fy barriers to adherence. If drug-related adverse effects
occur, appropriate management strategies should be
instituted. If adverse effects persist, switching to ano-
ther agent may be required. The decision to disconti-
nue or suspend therapy is based on the patient’s risk of
fracture and response to treatment, as well as the likeli-
hood of diminishing beneficial effects from the agent
used. Fracture risk after discontinuing therapy has not
been adequately evaluated.
Assessing response to osteoporosis therapy
Patients treated with pharmacological agents to impro-
ve bone strength and reduce fracture risk may not achie-
ve optimal skeletal benefit. Monitoring the effects of
therapy can inform the patient and physician whether
or not the drug is having its expected skeletal response
[63, 64].
Lacking direct tools for bone strength measurement
in living patients, we are presently limited to existing
surrogate ones [63, 64]. The available surrogate measu-
rements of bone strength, with the aim of osteoporosis
treatment benefit evaluation, are focused in literature
on the following four items:
1. BMD measurement is, to date, the most widely used
and probably the best long-term assessment of effi-
cacy of anti-fracture treatment.
2. The measurements of bone turnover markers (BTMs:
CTX, P1NP, OC) can be considered as a short-term
(at 3 months) surrogate monitoring tool in patients
treated with anti-catabolic (bisphosphonates, ralo-
xifene, hormone therapy, calcitonin) as well as ana-
bolic (PTH) drugs [65, 66, 12].
3. In both BTMs and BMD measurement, the least si-
gnificant change (LSC) method should be used for
interpretation of the results. Only compliant patients
may be defined as “nonresponders” or “suboptimal
responders”. In these cases, no significant changes
(according to LSC) of BMD or BTMs are observed
during treatment. A patient is defined as compliant
when she/he correctly takes at least 80% of the pre-
sented doses of the treatment in a minimal time in-
terval of one year [18, 17, 67].
4. The most controversial point appears to be the qu-
estion of whether an incident fracture is a reliable
clinical endpoint for the evaluation of the effective-
ness of therapy [63, 64].
The practical guidelines of monitoring therapy with
BMD are implemented to everyday good clinical prac-
tice by ISCD and IOF using LSC as an interpretation
tool, and extended for BTM use. BTM is evidenced as
the best short time surrogate marker to identify nonre-
sponders and/or non-compliers to therapy. A dose-de-
pendent decrease of BTMs has been consistently found
for HRT, SERMs, bisphosphonates, and denosumab.
Teriparatide induced a marked increase in BTMs. Re-
duction in bone turnover has been demonstrated as an
independent predictor of therapeutic efficacy on frac-
ture risk reduction in different studies. A meta-analysis
of several randomised clinical trials on osteoporosis tre-
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atment estimated that a 70% reduction in resorption
markers corresponds to a 40% reduction in the risk of
nonvertebral fractures, while a 50% reduction in bone
formation markers was associated with a 44% nonver-
tebral fracture risk reduction. The concept of LSC diffe-
rences, commonly applied to DXA measurements to
establish statistical significance of bone density chan-
ges in individual patients, is now also introduced for
BTM when using automated ECLIA machines for OC,
P1NP, and CTX measurements [18, 17, 67].
Fractures has not been shown as a reliable clinical
endpoint for evaluating the effectiveness of therapy in
individual patients because of its stochastic nature (i.e.
subject to randomness) that may or may not occur, re-
gardless of fracture probability [63, 64]. However, frac-
ture prevention is the primary aim of osteoporosis tre-
atment, and incident fracture frequency has been defi-
ned as the primary endpoint in all relevant osteoporo-
tic clinical trials (but with potential limits when judged
in a single patient). For this reason, incident fracture is
not necessarily a pharmacological treatment failure.
However, when a fracture occurs, other non-pharma-
cological intervention should be analysed (fall preven-
tion, balance training, muscle strengthening). A patients
is defined as a “nonresponder” or “suboptimal responder”
when, during treatment, a significant decrease in BMD
(below LSC) is observed and/or the patient does not have
the expected change in BTMs (below or above LSC).
Conclusions
Current treatment decisions in osteoporosis are based
on the results of comprehensive diagnostic procedures
(BMD, absolute risk of fracture, BTM). Since osteoporo-
sis is a chronic disease, long-term adherence to treat-
ment is important. Suitability of the drug, patient pre-
ference, tolerability and convenience should all be con-
sidered. Anti-catabolic drugs are most appropriate in
patients with high bone turnover, while anabolic drugs
demonstrate efficacy irrespective of bone turnover. Tre-
atment benefit evaluation in patients is crucial for im-
proving individual anti-fracture efficacy. BMD measu-
rement is most widely used for long-term assessment
of the efficacy of osteoporosis treatment. Measurements
of bone turnover markers (BTMs) can be considered
a useful short-term (at 3 months) monitoring tool in se-
lected patients. In both BTM and BMD the LSC method
should be used for interpretation of the results. Fractu-
res are not a reliable clinical endpoint for evaluating the
effectiveness of therapy in individual patients because
of their stochastic nature; however, if fractures occur,
the need for drug change and additional non-pharma-
cological treatment (fall prevention, balance training,
muscle strengthening) should always be considered.
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